The EU on Monday announced a multimillion-dollar investment in a German company that is working on a potential vaccine for COVID-19, amid reports that the US government was interested in acquiring the firm.
The funding is part of a coordinated EU response to the pandemic, making use of public and private funding to support research, the European Commission said.
“I am proud that we have leading companies like CureVac in the EU,” said European Commission President Ursula von der Leyen, Germany’s former minister of defense. “Their home is here, but their vaccines will benefit everyone, in Europe and beyond.”
Photo: Reuters
The EU’s executive body did not mention possible US interest in CureVac, but said it would provide up to 80 million euros (US$88 million) in support so that it can “scale up development and production of a vaccine against the coronavirus in Europe.”
CureVac on Monday denied reports that the US government was acting to acquire it.
“CureVac has not received from the US government or related entities an offer before, during and since the task force meeting in the White House on March 2,” the company said on Twitter.
The company’s then-chairman had met with US President Donald Trump at the White House as part of a discussion with numerous pharmaceutical executives.
Amid multiple reports that Trump was offering the firm a large amount of money to secure its work for the US, the White House said it was unaware of such “underlying information.”
German Chancellor Angela Merkel deflected a question about CureVac, referring to the company’s statement.
However, before CureVac’s tweet, Merkel’s chief of staff, Helge Braun, told the Bild daily that German officials had “very intensive contact” with CureVac over the past two weeks “when there were thoughts of enticing it to the United States.”
Braun said the firm would get the support it needs to develop a vaccine as quickly as possible for use in Germany and around the world.
In related news, US drugmaker Pfizer Inc has signed a deal with Germany’s BioNTech SE to codevelop a potential vaccine for COVID-19 using BioNTech’s mRNA-based drug development platform, the companies said yesterday.
The drugmakers are to start the collaboration immediately and have signed a letter of intent for the vaccine’s distribution outside China, they said in a joint statement.
The companies said they would finalize financial terms, and details regarding development, manufacturing and potential commercialization of the vaccine over the next few weeks.
Additional reporting by Reuters
A Ministry of Foreign Affairs official yesterday said that a delegation that visited China for an APEC meeting did not receive any kind of treatment that downgraded Taiwan’s sovereignty. Department of International Organizations Director-General Jonathan Sun (孫儉元) said that he and a group of ministry officials visited Shenzhen, China, to attend the APEC Informal Senior Officials’ Meeting last month. The trip went “smoothly and safely” for all Taiwanese delegates, as the Chinese side arranged the trip in accordance with long-standing practices, Sun said at the ministry’s weekly briefing. The Taiwanese group did not encounter any political suppression, he said. Sun made the remarks when
The Taiwanese passport ranked 33rd in a global listing of passports by convenience this month, rising three places from last month’s ranking, but matching its position in January last year. The Henley Passport Index, an international ranking of passports by the number of designations its holder can travel to without a visa, showed that the Taiwan passport enables holders to travel to 139 countries and territories without a visa. Singapore’s passport was ranked the most powerful with visa-free access to 192 destinations out of 227, according to the index published on Tuesday by UK-based migration investment consultancy firm Henley and Partners. Japan’s and
BROAD AGREEMENT: The two are nearing a trade deal to reduce Taiwan’s tariff to 15% and a commitment for TSMC to build five more fabs, a ‘New York Times’ report said Taiwan and the US have reached a broad consensus on a trade deal, the Executive Yuan’s Office of Trade Negotiations said yesterday, after a report said that Washington is set to reduce Taiwan’s tariff rate to 15 percent. The New York Times on Monday reported that the two nations are nearing a trade deal to reduce Taiwan’s tariff rate to 15 percent and commit Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) to building at least five more facilities in the US. “The agreement, which has been under negotiation for months, is being legally scrubbed and could be announced this month,” the paper said,
MIXED SOURCING: While Taiwan is expanding domestic production, it also sources munitions overseas, as some, like M855 rounds, are cheaper than locally made ones Taiwan and the US plan to jointly produce 155mm artillery shells, as the munition is in high demand due to the Ukraine-Russia war and should be useful in Taiwan’s self-defense, Armaments Bureau Director-General Lieutenant General Lin Wen-hsiang (林文祥) told lawmakers in Taipei yesterday. Lin was responding to questions about Taiwan’s partnership with allies in producing munitions at a meeting of the legislature’s Foreign Affairs and National Defense Committee. Given the intense demand for 155mm artillery shells in Ukraine’s defense against the Russian invasion, and in light of Taiwan’s own defensive needs, Taipei and Washington plan to jointly produce 155mm shells, said Lin,
RSS